CareDx, Inc
Health
Performance
6.8
Risk
Sell
Buy
Curious about the Scores? Learn more.

CareDx, Inc stock rating and score history

All changes in ratings, performance and outlook tracked over time.

16.07.2026
Picking up speed. Momentum turning positive.
01.07.2026
Fragile setup. Still failing to meet the key marks today.
01.07.2026
Health turning shaky. Something under the hood’s off.
02.06.2026
Trouble brewing. Volatility and pressure rising.
CDNA
CareDx, Inc
38.54
+0.44%
6.8
Sell
Buy
CareDx, Inc

CareDx, Inc stock price, chart patterns and momentum

Recent price movements, trend behaviour and momentum signals based on real-time market data.

What does CareDx, Inc do? Business model and key facts

Get the full picture of CareDx, Inc: what it builds, where it operates, and how it makes money.

CareDx, Inc Profile

Sector: Healthcare

Industry: Medical - Diagnostics & Research

Employees (FY): 765

CareDx, Inc. is a global innovator specializing in the discovery, development, and commercialization of diagnostic and management tools designed for transplant recipients and their healthcare providers. The company's extensive portfolio features a range of specialized diagnostic solutions for organ monitoring, including: AlloSure Kidney, AlloSure Heart, and AlloSure Lung: Advanced tests employing donor-derived cell-free DNA (dd-cfDNA) technology to assess the health of kidney, heart, and lung transplants, respectively. AlloMap Heart: A gene expression-based solution specifically for heart transplant patients. AlloSeq cfDNA: A broader surveillance tool to measure dd-cfDNA levels in the blood. CareDx also provides cutting-edge human leukocyte antigen (HLA) typing technologies, such as TruSight HLA, an NGS-based high-resolution typing solution; Olerup SSP, which uses sequence-specific primer technology for HLA allele typing; QTYPE for precise HLA typing; and AlloSeq Tx, another high-resolution HLA typing offering. For stem cell transplant recipients, the company offers AlloSeq HCT for chimerism testing. Beyond diagnostics, CareDx develops vital software and digital platforms to streamline transplant patient management. These include Ottr, a dedicated transplant patient management software; XynQAPI, focused on transplant quality tracking and waitlist management; and AlloCare, a mobile application serving as a patient-centric resource for those who have undergone transplantation. The company distributes its products directly to clients, as well as through a network of third-party distributors and sub-distributors. CareDx has forged significant partnerships, including a licensing agreement with Illumina, Inc. for the distribution, development, and commercialization of next-generation sequencing (NGS) products and technologies. Additionally, it collaborates with Cibiltech SAS to commercialize iBox, a software designed for the predictive analysis of kidney allograft loss post-transplantation. Founded in 1998, the company was initially known as XDx, Inc. before rebranding to CareDx, Inc. in March 2014. Its headquarters are located in South San Francisco, California.

shop
Company facts
John Walter Hanna Jr.
CEO
765
Employees worldwide
shop
Performance
202.27%
Last 12 months
-54.42%
Last 5 years
shop
Growth
$379.81M
Revenue year
$-21,354,000
Net income
shop
Valuation
$2.05B
Market Cap
-47.10
Price/Earnings Ratio

Stocks related to CareDx, Inc

Selected based on industry alignment and relative market positioning.

NEOG
Neogen Corporation
9.93
-0.80%
6.2
Sell
Buy
Neogen Corporation
VCYT
Veracyte, Inc.
59.53
+3.96%
6.0
Sell
Buy
Veracyte, Inc.
RDNT
RadNet, Inc.
61.87
+1.96%
7.0
Sell
Buy
RadNet, Inc.
CSTL
Castle Biosciences, Inc.
24.51
+2.57%
8.2
Sell
Buy
Castle Biosciences, Inc.
FLGT
Fulgent Genetics, Inc.
19.88
+1.38%
6.5
Sell
Buy
Fulgent Genetics, Inc.

Events and news impacting CareDx, Inc stock

Earnings, coporate decisions and industry developments that can affect the share price.

CareDx, Inc fundamentals and technical analysis

Financial fundamentals and technicals signals combined to access stability, momentum and market direction.